Reopening Laboratory Research at SMHS
Reopening Laboratory Research at SMHS
Augmenting the research portfolio and elevating its prominence through enhanced quality and impact.
These facilities offer a wide range of services, including cutting-edge technologies and high-end instrumentation coupled with technical support for research.
Coronavirus (COVID-19) Update: SMHS Research Re-Start PlansReopening Laboratory Research at SMHS
Plans for Reopening Laboratory Research at SMHS
Roster for SMHS Reopening Committees
Visit GW SMHS ON CAMPUS Policies and Guidelines website
Reopening Laboratory Research at SMHS
Moncef Slaoui, PhD, MBA, chief adviser for the COVID-19 vaccine development initiative Operation Warp Speed, visited GW on Oct. 21 to raise awareness for the national vaccine development efforts, encourage greater participation in the clinical trials and recognize GW for exceeding its enrollment goals for its vaccine trial.
A recent study by GW physicians on the severity of acute respiratory viral adverse events related to antirheumatic disease therapies found that some therapies may be associated with increased respiratory viral events while others don’t show increased frequency.
While COVID-19 infected patients should be treated with standard anticoagulation therapies, such as blood thinning medication, a new study by researchers at the George Washington University shows that anticoagulating patients at higher doses, without traditional medical indications to do so, may be ineffective and even harmful.
